Chronic Constipation Market Forecast
DelveInsight’s Chronic Constipation Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.
LAS VEGAS, NV, UNITED STATES, January 22, 2025 /EINPresswire.com/ --
DelveInsight’s “Chronic Constipation Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Constipation, historical and forecasted epidemiology as well as the Chronic Constipation market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Constipation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Constipation Market Forecast
Some of the key facts of the Chronic Constipation Market Report:
• The Chronic Constipation market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As per Yamamoto et al. (2022), an online survey in the United States indicated a 5.5% prevalence of chronic constipation using the Rome III criteria. In Japan, the prevalence was reported to be 2.1% based on medical consultations.
• Naronapride, and other emerging therapies are giving positive topline results, in their clinical trials. These emerging therapies are in mid phase of its clinical trials and are awaiting a launchwhich will make the pipeline robust.
• Key Chronic Constipation Companies: ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others
• Key Chronic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others
• The Chronic Constipation epidemiology based on gender analyzed that the prevalence of Chronic Constipation is higher in females than in males.
• The Chronic Constipation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Constipation pipeline products will significantly revolutionize the Chronic Constipation market dynamics.
Chronic Constipation Overview
Chronic constipation refers to a persistent and long-term condition characterized by infrequent bowel movements, difficulty passing stool, and a feeling of incomplete evacuation. It is typically defined as experiencing fewer than three bowel movements per week over an extended period.
Get a Free sample for the Chronic Constipation Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-constipation-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr
Chronic Constipation Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Constipation Epidemiology Segmentation:
The Chronic Constipation market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
• Total Prevalence of Chronic Constipation
• Prevalent Cases of Chronic Constipation by severity
• Gender-specific Prevalence of Chronic Constipation
• Diagnosed Cases of Episodic and Chronic Chronic Constipation
Download the report to understand which factors are driving Chronic Constipation epidemiology trends @ Chronic Constipation Epidemiology Forecast
Chronic Constipation Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Constipation market or expected to get launched during the study period. The analysis covers Chronic Constipation market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Constipation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Constipation Therapies and Key Companies
• LINZESS (linaclotide): ABBVIE
• GOOFICE: Eisai Co., Ltd.
• ANJ908 (Pradigastat): Anji Pharma
• YH12852: Yuhan
• Naronapride: Renexxion Ireland
• Linaclotide: Forest Laboratories
• A3309: Albireo
• AJG555: EA Pharma Co., Ltd.
• linaclotide: Astellas Pharma Inc
• KWA-0711: Kissei Pharmaceutical Co., Ltd.
• Tegaserod: Novartis
• TD-5108: Theravance Biopharma
• YKP10811: SK Life Science, Inc.
• prucalopride: Movetis
• KWA-0711: Kissei Pharmaceutical Co., Ltd
• PEG 4000 (Forlax®): Ipsen
Scope of the Chronic Constipation Market Report
• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Constipation Companies: ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others
• Key Chronic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others
• Chronic Constipation Therapeutic Assessment: Chronic Constipation current marketed and Chronic Constipation emerging therapies
• Chronic Constipation Market Dynamics: Chronic Constipation market drivers and Chronic Constipation market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Constipation Unmet Needs, KOL’s views, Analyst’s views, Chronic Constipation Market Access and Reimbursement
To know more about Chronic Constipation companies working in the treatment market, visit @ Chronic Constipation Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Constipation Market Report Introduction
2. Executive Summary for Chronic Constipation
3. SWOT analysis of Chronic Constipation
4. Chronic Constipation Patient Share (%) Overview at a Glance
5. Chronic Constipation Market Overview at a Glance
6. Chronic Constipation Disease Background and Overview
7. Chronic Constipation Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Constipation
9. Chronic Constipation Current Treatment and Medical Practices
10. Chronic Constipation Unmet Needs
11. Chronic Constipation Emerging Therapies
12. Chronic Constipation Market Outlook
13. Country-Wise Chronic Constipation Market Analysis (2019–2032)
14. Chronic Constipation Market Access and Reimbursement of Therapies
15. Chronic Constipation Market Drivers
16. Chronic Constipation Market Barriers
17. Chronic Constipation Appendix
18. Chronic Constipation Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
